Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Long-term immunosuppression and drug interactions.

G A Levy1

  • 1Multi Organ Transplant Program, Toronto General Hospital, University of Toronto, Ontario, Canada. glfgl2@attglobal.net

Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
|November 2, 2001
PubMed
Summary

Liver transplant survival is excellent, but long-term immunosuppression causes toxicity. New drugs and personalized protocols can reduce side effects and drug interactions for better patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Abstracts of presentations to the Annual Meetings of the Canadian Society of Colon and Rectal Surgeons Canadian Association of General Surgeons Canadian Association of Thoracic Surgeons: Canadian Surgery Forum, Toronto, Ont., September 6-9, 2007.

Canadian journal of surgery. Journal canadien de chirurgie·2023
Same author

Canadian Surgery Forum.

Canadian journal of surgery. Journal canadien de chirurgie·2022
Same author

Donor BMI >30 Is Not a Contraindication for Live Liver Donation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016
Same author

Overexpression of Fibrinogen-Like Protein 2 Promotes Tolerance in a Fully Mismatched Murine Model of Heart Transplantation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016
Same author

Live donor liver transplantation: a valid alternative for critically ill patients suffering from acute liver failure.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2015
Same author

Living vs. deceased donor liver transplantation provides comparable recovery of renal function in patients with hepatorenal syndrome: a matched case-control study.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2014

Area of Science:

  • Immunology
  • Hepatology
  • Pharmacology

Background:

  • Liver transplantation demonstrates high early patient and graft survival rates.
  • Long-term immunosuppression poses significant toxicity risks for liver transplant recipients.
  • Managing immunosuppression is critical for patient well-being post-transplant.

Purpose of the Study:

  • To highlight the need for reducing immunosuppression-related toxicity in liver transplant patients.
  • To explore the potential of novel pharmacological agents in mitigating immunosuppressive side effects.
  • To advocate for individualized immunosuppressive strategies tailored to each patient.

Main Methods:

  • Review of current literature on liver transplantation outcomes and immunosuppression.
  • Analysis of emerging immunosuppressive drugs and their therapeutic potential.

Related Experiment Videos

  • Discussion of personalized medicine approaches in post-transplant care.

    • Main Results:

    • Excellent early survival rates are achievable in liver transplantation.
    • Significant morbidity is linked to the toxicity of long-term immunosuppressive therapies.
    • Newer immunosuppressive drugs offer promise for reducing toxicity through combination or replacement therapies.
    • Drug interactions are a frequent complication, contributing to patient morbidity.

    Conclusions:

    • Focusing on reducing immunosuppression toxicity is paramount for improving long-term liver transplant outcomes.
    • Development of individualized immunosuppressive protocols is essential for patient care.
    • Strategic use of novel immunosuppressive agents can minimize adverse effects and drug interactions.